NAFLD/NASH

Progress your NAFLD/NASH preclinical research with CrownBio’s unique translational models
cvmd-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Understand the Pathophysiology of NAFLD/NASH with CrownBio Translational Models and Services

Nonalcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) is one of the most common causes of chronic liver disease and is a major public health problem worldwide.

  • NAFLD is more common among patients with obesity and Type 2 diabetes (T2D)

  • Affects up to 70% of patients

  • Clinical diagnosis still relies on invasive and costly liver biopsy

  • Results can be unreliable and lead to complications in fragile patients

CrownBio's models of NAFLD/NASH can help elucidate the pathophysiology for:

  • Improved diagnosis

  • Developing a greater understanding of disease progression

  • Studying promising candidates in the treatment of disease

Contact us today to discuss your NAFLD/NASH project needs and to experience the value of our expert service.